Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+1.37%
$101.84
100% positive prob.
5-Day Prediction
+2.72%
$103.20
100% positive prob.
20-Day Prediction
+4.28%
$104.77
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +1.37% | +2.72% | +4.28% | 100.0% | Pending |
| Q2 2026 | BUY | +1.31% | +2.79% | +3.36% | 100.0% | Pending |
| Q4 2025 | SELL | -0.71% | -1.68% | -0.02% | 99.9% | -2.30% |
SEC 8-K filings with transcript text
Oct 21, 2026 · 100% conf.
1D
+1.37%
$101.84
Act: +1.91%
5D
+2.72%
$103.20
20D
+4.28%
$104.77
2 abt-2026q3xexhibitx991.htm
Document
Exhibit 99.1
News Release
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
–Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent
–Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42
–Expands portfolio with key new product approvals
ABBOTT PARK, Ill., Oct. 21, 2026 — Abbott today announced financial results for the third quarter ended Sept. 30, 2026.
•Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis.
•Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.
•Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1.
•Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55.
•In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
•In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).
•In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk — the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States.
•In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation.
•In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.
"Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."
Page 1 of 21
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices
International7,509 1,304 1,452 1,614 3,139
Total reported13,013 2,262 3,305 1,614 5,826
% Change vs. 3Q25
U.S.28.0 7.9 109.2 n/a6.6
International6.2 3.1 6.2 6.8 7.2
Total reported14.5 5.1 46.7 6.8 6.9
Total reported excl. foreign exchange impact14.8 4.9 46.6 8.4 7.4
Comparable sales growth7.0 4.9 6.4 8.4 7.8
U.S.7.9 7.9 8.4 n/a7.6
International6.4 2.8 4.0 8.4 8.0
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices
International21,776 3,750 4,159 4,539 9,328
Total reported36,770 6,423 8,577 4,539 17,218
% Change vs. 9M25
U.S.17.7 (4.5)72.0 n/a7.1
International8.2 1.1 6.3 9.3 11.7
Total reported11.9 (1.3)32.4 9.3 9.6
Total reported excl. foreign exchange impact10.5 (2.1)30.8 8.7 7.8
Comparable sales growth5.2 (2.1)3.8 8.7 8.2
U.S.4.7 (4.5)4.9 n/a8.1
International5.7 (0.3)2.4 8.7 8.3
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 2 of 21
Nutrition
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions) TotalPediatricAdult
International1,304 486 818
Total reported2,262 1,063 1,199
% Change vs. 3Q25
Jul 16, 2026 · 100% conf.
1D
+1.31%
$100.10
Act: +1.88%
5D
+2.79%
$101.57
20D
+3.36%
$102.13
2 abt-2026q2xexhibitx991.htm
Document
Exhibit 99.1
News Release
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
–Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent
–Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31
–Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1
–Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58
–Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases
ABBOTT PARK, Ill., July 16, 2026 — Abbott today announced financial results for the second quarter ended June 30, 2026.
•Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis.
•Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items.
•Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1.
•Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.
•In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation.
•In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.
•In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
•In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360 left atrial appendage (LAA) device.
•In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC.
"Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
Page 1 of 21
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices
International7,377 1,273 1,432 1,499 3,173
Total reported12,593 2,144 3,092 1,499 5,853
% Change vs. 2Q25
U.S.22.0 (9.0)104.8 n/a7.0
International7.5 1.4 5.1 8.4 10.7
Total reported13.0 (3.1)42.3 8.4 9.0
Total reported excl. foreign exchange impact12.2 (3.6)41.3 8.7 7.9
Comparable sales growth4.8 (3.6)2.9 8.7 8.4
U.S.3.5 (9.0)4.0 n/a8.0
International5.8 0.6 1.6 8.7 8.7
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices
International14,267 2,446 2,707 2,925 6,189
Total reported23,757 4,161 5,272 2,925 11,392
% Change vs. 1H25
U.S.12.4 (10.3)52.5 n/a7.4
International9.3 — 6.4 10.7 14.2
Total reported10.5 (4.5)24.7 10.7 11.0
Total reported excl. foreign exchange impact8.2 (5.6)22.4 8.9 8.0
Comparable sales growth4.3 (5.6)2.4 8.9 8.4
U.S.3.0 (10.3)3.0 n/a8.3
International5.3 (1.9)1.6 8.9 8.5
Refer to pages 16 and 17 for a reconciliation of comparable
Apr 16, 2026
2 abt-2026q1xexhibitx991.htm
Document
Exhibit 99.1
News Release
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
–First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent
–Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market
–Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1
–Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences
ABBOTT PARK, Ill., April 16, 2026 — Abbott today announced financial results for the first quarter ended March 31, 2026.
•First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.
•First-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, which excludes specified items and reflects growth of 6 percent.
•On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's portfolio.
•Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.
•Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.
•In January, Abbott announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter (EV-ICD) system designed to deliver defibrillation therapy to people living with life-threatening heart rhythms.
•In February, Abbott announced positive early results from the VERITAS study that show clinically meaningful closure rates of the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).
•In March, Abbott announced results from the FreeDM2 randomized controlled trial, demonstrating that people with Type 2 diabetes on basal insulin who used FreeStyle Libre® achieved a 0.6% reduction in HbA1c and spent 2.5 more hours per day in the healthy glucose range compared to fingerstick monitoring.
"Our first-quarter results were aligned with our expectations to start the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year."
Page 1 of 15
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices
International6,890 1,173 1,275 1,426 3,016
Total reported11,164 2,017 2,180 1,426 5,539
% Change vs. 1Q25
U.S.2.5 (11.6)3.8 n/a7.9
International11.3 (1.5)7.8 13.2 18.0
Total reported7.8 (6.0)6.1 13.2 13.2
Total reported excl. foreign exchange impact3.8 (7.7)2.5 9.0 8.1
Comparable sales growth3.7 (7.7)1.8 9.0 8.5
U.S.2.5 (11.6)2.0 n/a8.7
International4.6 (4.7)1.6 9.0 8.3
Refer to page 13 for a reconciliation of comparable sales growth.
Page 2 of 15
Nutrition
First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions) TotalPediatricAdult
International1,173 442 731
Total reported2,017 953 1,064
% Change vs. 1Q25
International(1.5)(2.6)(0.9)
Total reported(6.0)(8.5)(3.6)
Total reported excl. foreign exchange impact(7.7)(9.7)(5.9)
Comparable sales growth(7.7)(9.7)(5.9)
International(4.7)(5.3)(4.3)
Worldwide Nutrition sales decreased 6.0 percent on a reported basis and 7.7 percent on a comparable basis in the first quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing act
This page provides Abbott Laboratories (ABT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ABT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.